BioNxt Solutions Résultats passés
Passé contrôle des critères 0/6
BioNxt Solutions's earnings have been declining at an average annual rate of -0.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 7.1% per year.
Informations clés
-0.4%
Taux de croissance des bénéfices
13.1%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 7.3% |
| Taux de croissance des recettes | 7.1% |
| Rendement des fonds propres | n/a |
| Marge nette | -20,944.3% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment BioNxt Solutions gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -6 | 3 | 2 |
| 31 Mar 24 | 0 | -8 | 4 | 2 |
| 31 Dec 23 | 0 | -8 | 4 | 3 |
| 30 Sep 23 | 0 | -13 | 4 | 2 |
| 30 Jun 23 | 0 | -13 | 4 | 2 |
| 31 Mar 23 | 0 | -12 | 4 | 2 |
| 31 Dec 22 | 0 | -12 | 4 | 2 |
| 30 Sep 22 | 0 | -14 | 6 | 2 |
| 30 Jun 22 | 0 | -14 | 8 | 2 |
| 31 Mar 22 | 0 | -17 | 9 | 3 |
| 31 Dec 21 | 0 | -21 | 12 | 3 |
| 30 Sep 21 | 0 | -15 | 10 | 3 |
| 30 Jun 21 | 0 | -19 | 12 | 4 |
| 31 Mar 21 | 0 | -19 | 11 | 4 |
| 31 Dec 20 | 0 | -17 | 11 | 3 |
| 30 Sep 20 | 0 | -16 | 10 | 3 |
| 30 Jun 20 | 0 | -13 | 10 | 2 |
| 31 Mar 20 | 0 | -10 | 9 | 1 |
| 31 Dec 19 | 0 | -8 | 6 | 1 |
| 30 Sep 19 | 0 | -6 | 5 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
Des revenus de qualité: BXT is currently unprofitable.
Augmentation de la marge bénéficiaire: BXT is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: BXT is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.
Accélération de la croissance: Unable to compare BXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: BXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement des fonds propres
ROE élevé: BXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.